Drug Type Antibody fusion proteins |
Synonyms CD86 x NKG2a (Shattuck Labs) |
Target |
Action agonists, inhibitors, antagonists |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), HLA-E inhibitors(major histocompatibility complex, class I, E inhibitors), NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Discovery | United States | - |